Kybernin P (Antithrombin Iii)

Antithrombin III in Kybernin P binds to and inactivates key clotting enzymes, primarily thrombin and factor Xa. By enhancing the natural inhibitory function of antithrombin, it reduces the generation of fibrin and limits clot formation during periods of increased thrombotic risk.

The dosage of Kybernin P is individualized. A qualified prescriber determines the appropriate amount based on the patient’s antithrombin activity, clinical condition, and therapeutic goals. Dosing regimens are not standardized and must follow professional medical guidance.

Safety data for Kybernin P in pregnancy and lactation are limited. Use should be considered only if the potential benefit justifies any potential risk to the fetus or infant, and decisions must be made by the treating physician in consultation with the patient.

To order Kybernin P, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and necessary import documentation.

Kybernin P is a purified antithrombin III concentrate, similar in function to other plasma‑derived antithrombin products. Compared with recombinant forms, it offers comparable efficacy in restoring antithrombin activity, but differences may exist in source material, purity, and regulatory status, which clinicians consider when selecting therapy.

Kybernin P must be stored refrigerated at 2‑8 °C, protected from light, and should not be frozen or shaken. Before use, inspect the solution for particulate matter or discoloration, and allow it to reach room temperature if required by the administration protocol.

Kybernin P is supplied as an intravenous solution and is administered by slow infusion into a vein under aseptic conditions. The infusion rate and duration are determined by the prescribing clinician, typically based on the patient’s antithrombin levels and clinical response.

Serious risks include severe allergic reactions such as anaphylaxis, significant bleeding due to excessive anticoagulation, and rare thrombotic events. Patients should be closely monitored for signs of hypersensitivity, bleeding, or unexpected clot formation during and after infusion.

Kybernin P is contraindicated in individuals with known hypersensitivity to antithrombin III or any component of the formulation. It should also be avoided in patients with active, uncontrolled bleeding or those for whom anticoagulation is contraindicated, unless a physician determines a clear benefit.